Publications by authors named "V E Seshan"

Background: Higher education is experiencing an increase in students with disabilities, necessitating considering their interests and well-being when preparing educational services. Students with disabilities make up one of the most significant minority groups among students in terms of diversity.

Aims: This study explored the experiences of students with disabilities at a university in the United Arab Emirates.

View Article and Find Full Text PDF

Ideally, detection of somatic mutations in a tumor is accomplished using a patient-matched sample of normal cells as the benchmark. In this way somatic mutations can be distinguished from rare germline mutations. In large retrospective studies, archival tissue collection can pose challenges in obtaining samples of normal DNA.

View Article and Find Full Text PDF

Background And Objective: Molecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB).

Methods: Targeted DNA and whole transcriptome RNA sequencing was performed on 100 UTUC tumors collected from patients undergoing nephroureterectomy.

View Article and Find Full Text PDF

Introduction: The entry to a professional course such as nursing is challenging for the students, due to its multifaceted curriculum and learning expectations.

Objectives: This study investigates the impact of peer tutoring on academic performance, psychological empowerment, and satisfaction among first-year nursing students.

Methods: A quantitative approach with one-group pre-test post-test design was utilized.

View Article and Find Full Text PDF

TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. Dual BTK and BCL2-inhibition with or without anti-CD20 monoclonal antibody therapy has shown promising activity in TP53-mutant MCL. We conducted a multi-center phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated MCL patients with TP53 mutation.

View Article and Find Full Text PDF